BMS309403 further reduced liver carcinogenesis in Stelic Animal Model (STAM) mice and reduced the sphere-forming, proliferation, and clonality of liver cancer stem cells, proposing FABP4 inhibition as an emerging therapeutic approach for end-stage liver disease [129]. Here, FABP4 is linked to End Stage Liver Disease.